Navigation Links
Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
Date:9/24/2007

Barcelona, Spain: Italian scientists will announce today (Monday September 24) that they have found a new and promising target for anti-tumour therapy in cancer. Professor Saverio Alberti, from the CESI, University of Chieti Foundation, Chieti, will tell the European Cancer Conference (ECCO 14) that he and his team have found a widespread mechanism for the stimulation of tumour growth in man, and that this is leading to the development of novel diagnostic and therapeutic procedures.

Professor Alberti and his team have discovered the function of the Trop-2 gene, a product of the TACTD2 gene, which is expressed in placenta, an invasive normal tissue. The function of Trop-2 was a mystery until now, says Professor Alberti, but knowing its expression in the trophoblast (cells forming the outer layer of the blastocyst the stage between the fertilised egg and the embryo) during pregnancy, we thought that it might well be involved in another invasive function tumour growth.

The scientists analysed the genes in human tumours and found that Trop-2 was expressed in the vast majority of human cancers, for example, breast, colon, stomach, lung, prostate, ovary, endometrium, uterine cervix and pancreas. Over-expression of the Trop-2 gene was also found when immunohistochemical (IHC) analysis of 1,755 tumours was undertaken. IHC analysis looks at the interaction of antibodies and antigens in tissues, and has the advantage of showing exactly where in a tissue a given protein is located. This has allowed us to develop anti-Trop-2 monoclonal antibodies for immunotherapy (modulation of the immune system to reject and destroy tumours) of Trop-2 expressing tumours, explains Professor Alberti.

Trop-2 over-expression was found in between 65% and 90% of the tumour types analysed, with an average of 74% across the board. These figures are high, explains Professor Alberti. In comparison, telomerase over-expression, possibly the most fundamental mechanism for cell immortalisation, is observed in 80% of all tumours. Telomerase is an enzyme that adds specific DNA repeats to the ends of chromosomes, so not strictly comparable. When we come to look at genes, her2/neu is a key determinant of breast cancer aggressiveness and is over-expressed in 25% of the cancers, and amplified in only a subgroup of them; and p53, possibly the most fundamental of tumour suppressors, is mutated and/or over-expressed in 50% of tumours. Mutations of the epidermal growth factor receptor gene (EGFR) are relatively infrequent in most cancers, reach 30% of the non small-cell lung cancers and are present at frequencies of around 75% in only a small subgroup of the latter. Most other markers known to date show lower figures and/or can be detected at high frequency in only a subgroup of tumours, for example PSA in prostate cancer. So Trop-2 really stands out.

It is also a unique marker of cancer metastases in different tumour types including colon, stomach, breast, and ovary in man and across a number of species, he says. In man, most metastases in lymph nodes or down-stream organs, for example liver in colon cancer, express higher levels of Trop-2 compared with the primary tumours. Trop-2 induces these metastases through mechanisms that the scientists are beginning to unravel. The most intriguing of these findings, they say, is the presence of two sequence elements in the Trop-2 cytoplasmic tail, the signalling engine of Trop-2, which act as, respectively, an enhancer and a silencer of metastatic propensity. This may be the key to the identification of signalling molecules that promote or inhibit the formation of metastases.

If we can identify such molecules we will be approaching a situation where we could influence their activity and hence either encourage or prevent it, says Professor Alberti. This could be an important step towards stopping cancer in its tracks.

In addition, the scientists want to extend their knowledge of the cell changes induced by receptor activation, or signal transduction pathways, triggered by Trop-2. This will be crucial for the better understanding of the way in which tumour growth is regulated by the gene, and will also provide additional targets for anti-cancer drugs, says Professor Alberti. We are very excited about the prospects for therapy which we can see arising from this discovery.


'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
44-078-030-48897
ECCO-the European CanCer Conference
Source:Eurekalert

Related medicine news :

1. OHSU Researchers Announce New Discovery
2. Discovery of bone gene
3. Latest discovery on Autism
4. Bacterial discovery may help CF patients
5. A new discovery about Acetaminophen
6. A new discovery about Acetaminophen
7. Resistant tumors could be treated with the discovery of a new molecule within cancer cells
8. Treatment for cholesterol-related illnesses likely with the discovery of receptor in mice
9. Ways to counter radiation effects with new molecule discovery
10. Canada stunned as mad cow discovery leads to beef ban
11. Mouth Infection better handled with new discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... at the University of California Berkeley, and other leading institutions in announcing the ... power of institutions to change the way animals are raised for food. , ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... Centers for Disease Control and Prevention (CDC), influenza vaccination should take ... communities across Massachusetts , Connecticut , ... through the end of the month. *Some exclusions apply ... ... by the end of October, according to the Centers for Disease Control ...
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
Breaking Medicine Technology: